Xultophy is a market of endocrine and metabolic disorder drugs. It is a combination of insulin degludec and liraglutide, two drugs used to treat type 2 diabetes. Xultophy is designed to help people with type 2 diabetes achieve better glycemic control with fewer injections and fewer side effects. It is a once-daily injection that helps to reduce the risk of hypoglycemia and weight gain. Xultophy is also used to reduce the risk of cardiovascular events in people with type 2 diabetes. Xultophy is a relatively new market, but it is growing rapidly. It is becoming increasingly popular among people with type 2 diabetes, as it offers a convenient and effective way to manage their condition. Companies in the Xultophy market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
